CY2015025I2 - Μεθοδοι για την αντιμετωπιση της νοσου παρκινσον - Google Patents

Μεθοδοι για την αντιμετωπιση της νοσου παρκινσον

Info

Publication number: CY2015025I2
Authority: CY; Cyprus
Prior art keywords: parkinson; disease; treatment; methods
Prior art date: 2003-04-11

Application number

CY2015025C

Other languages

English (en)

Other versions

CY2015025I1 (el

Original Assignee

Newron Pharmaceuticals S.P.A.

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2003-04-11

Filing date

2015-07-01

Publication date

2016-04-13

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=33159845&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY2015025(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2015-07-01 Application filed by Newron Pharmaceuticals S.P.A. filed Critical Newron Pharmaceuticals S.P.A.

2016-04-13 Publication of CY2015025I2 publication Critical patent/CY2015025I2/el

2016-04-13 Publication of CY2015025I1 publication Critical patent/CY2015025I1/el

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/48—Ergoline derivatives, e.g. lysergic acid, ergotamine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/485—Morphinan derivatives, e.g. morphine, codeine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs

Landscapes

Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Epidemiology (AREA)
Emergency Medicine (AREA)
Biomedical Technology (AREA)
Bioinformatics & Cheminformatics (AREA)
Neurology (AREA)
Engineering & Computer Science (AREA)
Neurosurgery (AREA)
Organic Chemistry (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Psychology (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

CY2015025C 2003-04-11 2015-07-01 Μεθοδοι για την αντιμετωπιση της νοσου παρκινσον CY2015025I1 (el)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US46220503P	2003-04-11	2003-04-11
PCT/IB2004/001408 WO2004089353A2 (en)	2003-04-11	2004-04-08	Methods for treatment of parkinson's disease

Publications (2)

Publication Number	Publication Date
CY2015025I2 true CY2015025I2 (el)	2016-04-13
CY2015025I1 CY2015025I1 (el)	2016-04-13

Family

ID=33159845

Family Applications (3)

Application Number	Title	Priority Date	Filing Date
CY20091100857T CY1109295T1 (el)	2003-04-11	2009-08-12	Μεθοδοι για την αντιμετωπιση της νοσου παρκινσον
CY20141100288T CY1115286T1 (el)	2003-04-11	2014-04-15	Μεθοδοι θεραπευτικης αγωγης της νοσου toy parkinson
CY2015025C CY2015025I1 (el)	2003-04-11	2015-07-01	Μεθοδοι για την αντιμετωπιση της νοσου παρκινσον

Family Applications Before (2)

Application Number	Title	Priority Date	Filing Date
CY20091100857T CY1109295T1 (el)	2003-04-11	2009-08-12	Μεθοδοι για την αντιμετωπιση της νοσου παρκινσον
CY20141100288T CY1115286T1 (el)	2003-04-11	2014-04-15	Μεθοδοι θεραπευτικης αγωγης της νοσου toy parkinson

Country Status (28)

Country	Link
US (3)	US8283380B2 (el)
EP (2)	EP2070526B1 (el)
JP (2)	JP2006522800A (el)
KR (2)	KR101129015B1 (el)
CN (2)	CN1771030A (el)
AR (1)	AR044007A1 (el)
AT (1)	ATE435012T1 (el)
AU (1)	AU2004228782B2 (el)
BR (1)	BRPI0409364A (el)
CA (1)	CA2523188C (el)
CY (3)	CY1109295T1 (el)
DE (1)	DE602004021790D1 (el)
DK (2)	DK2070526T3 (el)
ES (2)	ES2326373T3 (el)
FR (1)	FR15C0054I2 (el)
HU (1)	HUS1500043I1 (el)
IL (2)	IL171331A (el)
LU (1)	LU92782I2 (el)
MX (1)	MXPA05010873A (el)
NL (1)	NL300752I2 (el)
NO (3)	NO334316B1 (el)
NZ (1)	NZ542910A (el)
PL (2)	PL1613296T3 (el)
PT (2)	PT2070526E (el)
RU (1)	RU2342929C2 (el)
SI (2)	SI2070526T1 (el)
TW (1)	TWI340640B (el)
WO (1)	WO2004089353A2 (el)

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB9727523D0 (en)	1997-12-31	1998-02-25	Pharmacia & Upjohn Spa	Alpha-aminoamide derivatives useful as analgesic agents
BRPI0212298B8 (pt) *	2001-09-03	2021-05-25	Newron Pharm Spa	composição farmacêutica compreendendo gabapentina ou um análogo da mesma e (alfa)-aminoamida e seu uso analgésico
EP1438956A1 (en) *	2003-01-16	2004-07-21	Newron Pharmaceuticals S.p.A.	Alpha-aminoamide derivatives useful as antimigraine agents
RU2396251C2 (ru) *	2003-08-25	2010-08-10	Ньюрон Фармасьютикалс, Спа	Производные альфа-аминоамидов, применимые в качестве противовоспалительных агентов
EP1588704A1 (en)	2004-04-22	2005-10-26	Newron Pharmaceuticals S.p.A.	Alpha-aminoamide derivatives useful in the treatment of restless legs syndrome and addictive disorders
AU2005282028B2 (en) *	2004-09-10	2011-03-24	Newron Pharmaceuticals S.P.A.	(halobenzyloxy) benzylamino-propanamides as sodium and/or calcium channel selective modulators
US20070004639A1 (en) *	2005-07-01	2007-01-04	Bodybio, Inc.	Methods and compositions for treating Parkinson's disease
EP1954256A2 (en)	2005-11-09	2008-08-13	Torrent Pharmaceuticals Ltd	Pharmaceutical composition comprising a compound having a catechol moiety and an alkalising agent
SI1963280T1 (sl) *	2005-12-22	2016-02-29	Newron Pharmaceuticals S.P.A.	2-feniletilamino derivati kot modulatorji kalcijevih in/ali natrijevih kanalčkov
CN101032474B (zh) *	2006-03-06	2011-02-16	重庆医药工业研究院有限责任公司	一种治疗或预防神经系统疾病的雷沙吉兰透皮贴片及其制备方法
EP1870097A1 (en) *	2006-06-15	2007-12-26	Newron Pharmaceuticals S.p.A.	Alpha-aminoamide derivatives useful in the treatment of cognitive disorders
US8106056B2 (en) *	2006-06-16	2012-01-31	Solvay Pharmaceuticals B.V.	Combination preparations comprising bifeprunox and a dopamine agonist
EA025326B1 (ru) *	2006-06-19	2016-12-30	Ньюрон Фармасьютикалс С.П.А.	Применение сафинамида и ралфинамида высокой степени чистоты для лечения заболеваний и болезненных состояний в условиях, не препятствующих активности цитохромов системы cyp450 и не проявляющих блокирующих свойств в отношении herg канала
DE102007014947B4 (de) *	2007-03-23	2010-05-27	Axxonis Pharma Ag	Stabilisierte wässrige Lösungen von Ergolinverbindungen
US20100092554A1 (en) *	2007-04-24	2010-04-15	Boehringer Ingelheim International Gmbh	Combination with an extended release tablet formulation containing pramipexole or a pharmaceutically acceptable salt thereof
US8519000B2 (en)	2007-06-15	2013-08-27	Newron Pharmaceuticals S.P.A.	Substituted 2-[2-(phenyl) ethylamino] alkaneamide derivatives and their use as sodium and/or calcium channel modulators
GB2453770A (en) *	2007-10-19	2009-04-22	Reckitt Benckiser Healthcare	Oral composition comprising a cooling agent
WO2009054964A1 (en) *	2007-10-22	2009-04-30	Concert Pharmaceuticals, Inc.	Alpha-aminoamide derivatives
US8530701B2 (en)	2007-12-11	2013-09-10	Newron Pharmaceuticals, S.P.A.	High purity 2-[4-(3- OR 2-fluorobenzyloxy)benzylamino]propanamides and methods of use thereof
JP5736175B2 (ja) *	2007-12-19	2015-06-17	ニユーロン・フアーマシユーテイカルズ・エツセ・ピー・アー	精神障害の治療に有用なα−アミノアミド誘導体
WO2009122351A2 (en) *	2008-04-01	2009-10-08	Kangwon National University	Anti-parkinsonian compounds mppe
EP2285769B1 (en) *	2008-06-02	2014-08-13	Generics [UK] Limited	A process for the preparation of enantiomerically pure amines
AU2009254929B2 (en) *	2008-06-02	2014-03-13	Generics [Uk] Limited	An improved process for the preparation of amines
WO2009147681A1 (en) *	2008-06-06	2009-12-10	Pharma Two B Ltd.	Pharmaceutical compositions for treatment of parkinson's disease
AU2009258151A1 (en) *	2008-06-13	2009-12-17	Teva Pharmaceutical Industries, Ltd.	Rasagiline for Parkinson's disease modification
WO2010010138A1 (en) *	2008-07-24	2010-01-28	Boehringer Ingelheim International Gmbh	Pharmaceutical composition comprising pramipexole and a calcium channel blocker for the treatment of parkinson's disease
EP2218444A3 (en) *	2009-01-23	2010-08-25	Teva Pharmaceutical Industries, Ltd.	Delayed release rasagiline formulation
US20100189791A1 (en) *	2009-01-23	2010-07-29	Teva Pharmaceutical Industries, Ltd.	Delayed release rasagiline malate formulation
EP2314569A1 (en)	2009-10-22	2011-04-27	Merck Patent GmbH	Novel polymorphic forms of (S)-2-[4-(3-Fluoro-benzyloxy)-benzylamino]-propionamide mesylate salt and processes of manufacturing thereof
CN102048717B (zh)	2009-10-29	2014-02-19	重庆医药工业研究院有限责任公司	一种稳定的雷沙吉兰组合物
WO2011098456A1 (en)	2010-02-09	2011-08-18	Merck Serono S.A.	Safinamide in the treatment of dyskinesia
KR101851118B1 (ko)	2010-04-27	2018-04-23	뉴론 파마슈티칼즈 에스. 피. 에이.	랄핀아미드 메탄설포네이트 염들 또는 이들의 ｒ―에난티오머들의 제조 방법
AP3030A (en)	2010-04-30	2014-11-30	Teikoku Pharma Usa Inc	Propynylaminoindan transdermal compositions
WO2012129429A2 (en)	2011-03-24	2012-09-27	Teikoku Pharma Usa, Inc.	Transdermal compositions comprising an active agent layer and an active agent conversion layer
US20140227184A1 (en)	2011-08-19	2014-08-14	The Trustees Of Princeton University	C-halogen bond formation
US20150031768A1 (en) *	2011-08-19	2015-01-29	The Trustees Of Princeton University	C-halogen bond formation
WO2013070526A1 (en)	2011-11-09	2013-05-16	Teikoku Pharma Usa, Inc.	Methods for the treatment of skin neoplasms
KR20150059177A (ko)	2012-11-02	2015-05-29	테이코쿠 팔마 유에스에이, 인코포레이티드	프로피닐아미노인단 경피 조성물
US9155695B2 (en)	2013-03-14	2015-10-13	Medtronic, Inc.	Injectable ropinirole compositions and methods for making and using same
WO2014210544A2 (en) *	2013-06-27	2014-12-31	Cedars-Sinai Medical Center	Adrenoceptors antagonists for the prevention and treatment of neurodegenerative conditions
BR112016024502A8 (pt) *	2014-04-21	2021-06-29	Civitas Therapeutics Inc	uso de uma dose de partículas finas (fdp) de levodopa na fabricação de um medicamento
AU2015324914B2 (en) *	2014-10-02	2018-10-04	Neurobiogen Co., Ltd.	Alpha-aminoamide derivative compound and pharmaceutical composition containing the same
ES2764490T3 (es) *	2015-08-27	2020-06-03	Prexton Therapeutics Sa	Derivado de oxima de cromona que penetra en el cerebro para la terapia de la discinesia inducida por levodopa
WO2017161155A1 (en) *	2016-03-17	2017-09-21	The Johns Hopkins University	Methods for preventing or treating parkinson's disease by the farnesylation of paris
ITUA20163981A1 (it)	2016-05-31	2017-12-01	Zambon Spa	Composizioni farmaceutiche comprendenti safinamide
EP3568082A4 (en) *	2017-01-14	2020-12-09	Neurrx, SPC	METHOD OF USE OF HUMAN EXCREMENTS AND SECRETIONS FOR THE EARLY DETECTION OF PARKINSON'S DISEASE
CN109251155A (zh) *	2017-07-14	2019-01-22	广东东阳光药业有限公司	α-氨基酰胺衍生物及其用途
WO2019036624A1 (en) *	2017-08-17	2019-02-21	Gu Zi Qiang	MONOAMINE PAMOATE SALT TYPE ANTI-PARKINSON AGENTS, PROCESS FOR PREPARING AND USING SAME
WO2019086408A1 (en)	2017-11-02	2019-05-09	Zambon S.P.A.	Pharmaceutical compositions comprising safinamide
KR102005019B1 (ko) *	2018-04-04	2019-07-31	한국과학기술연구원	뇌졸중의 예방 및 치료용 조성물
US11083715B2 (en) *	2019-09-12	2021-08-10	Achieve Life Sciences, Inc.	Compositions comprising cytisine in the treatment and/or prevention of addiction in subjects in need thereof
LU101477B1 (en) *	2019-11-12	2021-05-14	Univ Luxembourg	An inhibitor of an iron-containing hydrogenase of a methanogenic archaeon for use in the treatment or prevention of a parkinsonian condition
CN110938014A (zh) *	2019-11-28	2020-03-31	岳千奥	取代苯氧酰胺衍生物、应用及用于治疗帕金森病的药物
US20230028539A1 (en) *	2019-12-06	2023-01-26	Shanghai Pharmaceuticals Holding Co., Ltd.	Pharmaceutical composition, complementary kit and application thereof
CN110999980A (zh) *	2019-12-19	2020-04-14	新疆石河子职业技术学院（石河子市技工学校）	一种葡萄酒洗浸奶酪加工方法
WO2022047298A1 (en) *	2020-08-31	2022-03-03	Purdue Pharma L.P.	Compositions and methods for levodopa delivery

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB1140748A (en)	1966-06-23	1969-01-22	Ici Ltd	New carboxylic acid derivatives
US3795739A (en) *	1972-02-14	1974-03-05	Hoffmann La Roche	Treatment of parkinson disease
US4049663A (en)	1972-06-06	1977-09-20	Allen & Hanburys Limited	Ethylene diamine derivatives
FR2480747A1 (fr)	1980-04-17	1981-10-23	Roques Bernard	Derives d'acides amines et leur application therapeutique
US4935429A (en)	1985-10-25	1990-06-19	Dackis Charles A	Method of treating psychostimulant addiction
ES2042520T3 (es) *	1986-06-10	1993-12-16	Chiesi Farma Spa	Composiciones farmaceuticas que contienen el ester metilico de levodopa, preparacion y aplicaciones terapeuticas del mismo.
EP0331620B1 (de)	1988-03-01	1993-08-11	Birkmayer, Walther, Prof. Dr.	Mittel zur Behandlung des Parkinson-Syndroms
IL94466A (en)	1989-05-25	1995-01-24	Erba Carlo Spa	Pharmaceutical preparations containing the history of A-amino carboxamide N-phenylalkyl are converted into such new compounds and their preparation
US5221536A (en) *	1990-05-07	1993-06-22	Alza Corporation	Dosage form indicated for the management of abnormal posture, tremor and involuntary movement
US5502658A (en)	1990-12-27	1996-03-26	Relin; Arkadi	Sampled-continuous probability method of velocity measurement of the object having informatively-structural inhomogeneity
GB9306886D0 (en)	1993-04-01	1993-05-26	Erba Carlo Spa	Substituted (arylakoxybenzyl) aminopropanamide derivatives and process for their preparation
IL111240A (en) *	1993-10-18	2001-10-31	Teva Pharma	Salts of r(+) - enantiomers of n- propargyl-1-aminoindan and pharmaceutical compositions comprising them
JPH11505828A (ja) *	1995-05-26	1999-05-25	ファイザー・インコーポレーテッド	パーキンソン症候群の治療用の選択的ｎｍｄａアンタゴニスト含有組合せ
GB9515412D0 (en) *	1995-07-27	1995-09-27	Pharmacia Spa	2-(4-substituted)-benzylamino-2-methyl-propanamide derivatives
GB9727523D0 (en)	1997-12-31	1998-02-25	Pharmacia & Upjohn Spa	Alpha-aminoamide derivatives useful as analgesic agents
FI109453B (fi)	1999-06-30	2002-08-15	Orion Yhtymae Oyj	Farmaseuttinen koostumus
US20020019421A1 (en) *	2000-07-05	2002-02-14	Roni Biberman	Compositions and therapy for substance addiction
DE10041479A1 (de) *	2000-08-24	2002-03-14	Sanol Arznei Schwarz Gmbh	Neue pharmazeutische Zusammensetzung zur Verabreichung von N-0923
FR2829027A1 (fr) *	2001-08-29	2003-03-07	Aventis Pharma Sa	Association avec un antagoniste du recepteur cb1, les compositions pharmaceutiques les contenant et leur utilisation pour le traitement de la maladie de parkinson

2004
- 2004-04-07 AR ARP040101189A patent/AR044007A1/es unknown
- 2004-04-08 JP JP2006506582A patent/JP2006522800A/ja active Pending
- 2004-04-08 MX MXPA05010873A patent/MXPA05010873A/es active IP Right Grant
- 2004-04-08 AT AT04726590T patent/ATE435012T1/de active
- 2004-04-08 DE DE602004021790T patent/DE602004021790D1/de not_active Expired - Lifetime
- 2004-04-08 WO PCT/IB2004/001408 patent/WO2004089353A2/en active Application Filing
- 2004-04-08 ES ES04726590T patent/ES2326373T3/es not_active Expired - Lifetime
- 2004-04-08 DK DK09154864.4T patent/DK2070526T3/da active
- 2004-04-08 ES ES09154864.4T patent/ES2454272T3/es not_active Expired - Lifetime
- 2004-04-08 PT PT91548644T patent/PT2070526E/pt unknown
- 2004-04-08 SI SI200432150T patent/SI2070526T1/sl unknown
- 2004-04-08 RU RU2005131422/15A patent/RU2342929C2/ru active
- 2004-04-08 PT PT04726590T patent/PT1613296E/pt unknown
- 2004-04-08 TW TW093109755A patent/TWI340640B/zh not_active IP Right Cessation
- 2004-04-08 CN CNA200480009655XA patent/CN1771030A/zh active Pending
- 2004-04-08 KR KR1020057019264A patent/KR101129015B1/ko not_active Expired - Lifetime
- 2004-04-08 SI SI200431192T patent/SI1613296T1/sl unknown
- 2004-04-08 US US10/559,982 patent/US8283380B2/en active Active
- 2004-04-08 AU AU2004228782A patent/AU2004228782B2/en not_active Expired
- 2004-04-08 BR BRPI0409364-0A patent/BRPI0409364A/pt not_active Application Discontinuation
- 2004-04-08 DK DK04726590T patent/DK1613296T3/da active
- 2004-04-08 PL PL04726590T patent/PL1613296T3/pl unknown
- 2004-04-08 CN CN201110271872.8A patent/CN102274517B/zh not_active Expired - Lifetime
- 2004-04-08 EP EP09154864.4A patent/EP2070526B1/en not_active Expired - Lifetime
- 2004-04-08 EP EP04726590A patent/EP1613296B1/en not_active Expired - Lifetime
- 2004-04-08 NZ NZ542910A patent/NZ542910A/en not_active IP Right Cessation
- 2004-04-08 KR KR1020117013555A patent/KR20110070929A/ko not_active Ceased
- 2004-04-08 PL PL09154864T patent/PL2070526T3/pl unknown
- 2004-04-08 CA CA2523188A patent/CA2523188C/en not_active Expired - Lifetime
2005
- 2005-10-10 IL IL171331A patent/IL171331A/en active Protection Beyond IP Right Term
- 2005-10-10 NO NO20054640A patent/NO334316B1/no active Protection Beyond IP Right Term
2009
- 2009-08-12 CY CY20091100857T patent/CY1109295T1/el unknown
2011
- 2011-11-17 IL IL216403A patent/IL216403A/en active IP Right Grant
2012
- 2012-08-24 US US13/594,621 patent/US8901176B2/en not_active Expired - Lifetime
- 2012-12-14 JP JP2012273371A patent/JP2013067647A/ja active Pending
2013
- 2013-10-28 NO NO20131417A patent/NO335537B1/no unknown
2014
- 2014-04-15 CY CY20141100288T patent/CY1115286T1/el unknown
- 2014-11-04 US US14/532,925 patent/US9492410B2/en not_active Expired - Fee Related
2015
- 2015-07-01 CY CY2015025C patent/CY2015025I1/el unknown
- 2015-07-17 NL NL300752C patent/NL300752I2/nl unknown
- 2015-07-22 FR FR15C0054C patent/FR15C0054I2/fr active Active
- 2015-07-22 LU LU92782C patent/LU92782I2/xx unknown
- 2015-07-22 HU HUS1500043C patent/HUS1500043I1/hu unknown
- 2015-07-23 NO NO2015018C patent/NO2015018I1/no not_active IP Right Cessation

Also Published As

Publication number	Publication date
AR044007A1 (es)	2005-08-24
KR20110070929A (ko)	2011-06-24
WO2004089353A3 (en)	2004-12-16
PL2070526T3 (pl)	2014-08-29
FR15C0054I2 (fr)	2018-01-26
WO2004089353A8 (en)	2005-09-01
US8901176B2 (en)	2014-12-02
AU2004228782A1 (en)	2004-10-21
IL216403A0 (en)	2011-12-29
EP2070526A1 (en)	2009-06-17
MXPA05010873A (es)	2006-03-21
SI2070526T1 (sl)	2014-05-30
CY1109295T1 (el)	2014-07-02
US9492410B2 (en)	2016-11-15
TWI340640B (en)	2011-04-21
DK1613296T3 (da)	2009-10-05
JP2006522800A (ja)	2006-10-05
ATE435012T1 (de)	2009-07-15
CY1115286T1 (el)	2017-01-04
FR15C0054I1 (fr)	2015-11-09
PT2070526E (pt)	2014-03-31
CN102274517A (zh)	2011-12-14
LU92782I2 (fr)	2015-09-22
NO2015018I1 (no)	2015-08-03
PL1613296T3 (pl)	2009-12-31
RU2005131422A (ru)	2006-04-27
DE602004021790D1 (de)	2009-08-13
US20130053368A1 (en)	2013-02-28
CN102274517B (zh)	2018-08-31
ES2454272T3 (es)	2014-04-10
SI1613296T1 (sl)	2009-10-31
CY2015025I1 (el)	2016-04-13
EP1613296B1 (en)	2009-07-01
BRPI0409364A (pt)	2006-04-25
EP1613296A2 (en)	2006-01-11
DK2070526T3 (da)	2014-03-24
IL216403A (en)	2015-01-29
IL171331A (en)	2012-03-29
AU2004228782B2 (en)	2010-05-20
CA2523188A1 (en)	2004-10-21
US20150150833A1 (en)	2015-06-04
KR20060010745A (ko)	2006-02-02
CN1771030A (zh)	2006-05-10
NO20054640D0 (no)	2005-10-10
NO2015018I2 (no)	2015-07-23
RU2342929C2 (ru)	2009-01-10
NO20054640L (no)	2005-12-09
US20070093495A1 (en)	2007-04-26
PT1613296E (pt)	2009-07-30
KR101129015B1 (ko)	2012-04-20
NL300752I2 (el)	2016-07-05
NO334316B1 (no)	2014-02-03
CA2523188C (en)	2012-09-25
NO335537B1 (no)	2014-12-22
EP2070526B1 (en)	2014-02-26
HUS1500043I1 (hu)	2018-11-28
US8283380B2 (en)	2012-10-09
JP2013067647A (ja)	2013-04-18
TW200505423A (en)	2005-02-16
WO2004089353A2 (en)	2004-10-21
NO20131417L (no)	2005-12-09
ES2326373T3 (es)	2009-10-08
NZ542910A (en)	2007-10-26

Publication	Publication Date	Title
CY2015025I2 (el)	2016-04-13	Μεθοδοι για την αντιμετωπιση της νοσου παρκινσον
IL224393B (en)	2018-06-28	Compositions for treatment of huntington's disease
EP1940373B8 (en)	2015-06-24	1-fluoro-1-deoxy-scyllo-inositol for the treatment of alzheimer's disease
EP1643986A4 (en)	2009-04-08	PHENYLCARBOXYLATE BETA-SECRETASE INHIBITORS FOR THE TREATMENT OF ALZHEIMER'S DISEASE
ATE440866T1 (de)	2009-09-15	Nogo-a-neutralisierende immunglobuline zur behandlung neurologischer krankheiten
DE602004020072D1 (de)	2009-04-30	1,2,3,4-tetrasubstituiertes indol zur behandlung von atemwegserkrankungen
NO20043237L (no)	2004-08-02	Dihydrobenzodiazepin-2-onderivater for behandling av neurologiske forstyrrelser
DE60322451D1 (de)	2008-09-04	4-Tetrazolyl-4-Phenylpiperidinderivate zur Schmerzbehandlung
CY2013022I1 (el)	2020-05-29	Συνθεσεις για την θεραπευτικη αγωγη γαστρεντερικων διαταραχων
HK1091732A1 (en)	2007-01-26	Use of modified cyclosporins for the treatment of hcv disorders
ES2414872T8 (es)	2014-11-06	Terapia combinada para la prevención o tratamiento de la enfermedad de Alzheimer y kit correspondiente
AU2003206413A8 (en)	2003-07-24	Substituted amino carboxamides for the treatment of alzheimer's disease
GB0329874D0 (en)	2004-01-28	Compounds useful for the treatment of diseases
EP1680145A4 (en)	2007-05-23	METHODS AND COMPOSITIONS FOR THE TREATMENT OF NEUROLOGICAL DISEASES
DE502004010131D1 (de)	2009-11-05	Pyridopyrimidinone zur behandlung von krebserkrankungen
ITMI20031311A0 (it)	2003-06-27	Formulazioni per il trattamento di disturbi artrosici
GB0320238D0 (en)	2003-10-01	Treatment of disease
EP1611120A4 (en)	2008-04-23	NEW M THODES FOR THE TREATMENT OF INFLAMMATORY DISEASES
AU2003254146A1 (en)	2005-03-07	Methods for the treatment of parkinson's disease
IL184849A0 (en)	2007-12-03	Organic compounds useful for the treatment of alzheimer's disease, their use and method of preparation
IL172690A0 (en)	2006-04-10	Methods for the diagnosis and prognosis of alzheimer's disease
IS8477A (is)	2006-05-22	Beta-laktöm til að meðhöndla MTK sjúkdóma
AU2003297912A8 (en)	2004-07-09	Methods for screening compounds for use in the treatment of disease
GB0410101D0 (en)	2004-06-09	Parkinson's disease
AU2003216696A8 (en)	2003-10-27	Methods for the selection of compounds useful for the treatment of huntington's disease